MDA 2021

#MDA2021 — Amondys 45 Safe and Well-tolerated in Phase 1/2 Trial

Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Treatment with Amondys 45 was safe and well-tolerated, showing little to no evidence of accumulation in the blood…

#MDA2021 — Patients Switched to Emflaza for Efficacy, Tolerability

Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Switching from prednisone to Emflaza (deflazacort) successfully met efficacy and tolerability goals in most patients with Duchenne…